Pemvidutide Australia: Research Overview

The short answer

Pemvidutide, also known by the code name ALT-801, is an investigational peptide developed by Altimmune. It is described as a GLP-1 and glucagon dual receptor agonist and sits within the next wave of metabolic research compounds. As reported to date, pemvidutide has been studied in clinical trials but is not an approved medicine with any major regulator. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not TGA-approved. NovaPeptides supplies pemvidutide strictly for laboratory research use only, not for human use.

What pemvidutide is

Pemvidutide is a synthetic peptide. In published materials it is identified by the developmental code name ALT-801 and is developed by the clinical-stage biopharmaceutical company Altimmune. It belongs to a class of molecules often described as incretin-based or metabolic peptides, and more specifically as a dual receptor agonist.

The term dual receptor agonist means the molecule is designed to interact with two distinct receptor targets rather than one. In the case of pemvidutide, those targets are the GLP-1 receptor and the glucagon receptor. This places it alongside other investigational dual agonists in the broader metabolic research field, as opposed to single-target molecules that act at only one receptor.

Identity at a glance

• Common research name: pemvidutide
• Developmental code name: ALT-801
• Developer: Altimmune
• Molecule type: synthetic peptide
• Described class: GLP-1 and glucagon dual receptor agonist

How it works at the science level

Pemvidutide is characterised in the scientific literature as a balanced dual agonist of the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). An agonist is a molecule that binds to and activates a receptor. By acting at two receptors at once, dual agonists are studied for how the two signalling pathways combine, rather than for a single mechanism in isolation.

At the GLP-1 receptor, GLP-1 pathway activation is associated in research with effects on glucose-dependent signalling and appetite-related pathways in the brain. At the glucagon receptor, glucagon pathway activation is studied in connection with energy expenditure and hepatic (liver) lipid metabolism. The scientific interest in pemvidutide centres on how a roughly balanced activation of both receptors behaves in laboratory and clinical research settings.

This description is provided at a mechanistic level only. It is not a statement about outcomes for any individual and does not imply any effect a reader should expect. NovaPeptides supplies the compound for laboratory research use only.

Clinical trial stage

Pemvidutide has progressed through several clinical research programmes run by Altimmune. These studies carry programme names that appear in the company's public announcements. The descriptions below summarise what the trials have been reported to study, not what any reader should expect.

Reported trial programmes

• MOMENTUM: a Phase 2 trial that studied pemvidutide in obesity.
• IMPACT: a Phase 2b trial that studied pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
• PERFORMA: a Phase 3 trial in MASH that, as reported, has moved into patient enrolment.
• Additional Phase 2 programmes have been reported in alcohol use disorder and alcohol-associated liver disease.

In broad terms, as reported to date, pemvidutide has completed mid-stage (Phase 2 and Phase 2b) trials and has advanced toward late-stage (Phase 3) evaluation in at least one indication. It remains an investigational compound. Being in or past Phase 2 or Phase 3 trials is not the same as regulatory approval, and trial activity does not change its status as an unapproved investigational molecule.

The U.S. Food and Drug Administration has been reported to grant certain expedited-review designations to pemvidutide in some indications. These are procedural designations within a review process and are not marketing approval.

Regulatory status in Australia

In Australia, therapeutic goods must generally be entered on the Australian Register of Therapeutic Goods (ARTG), maintained by the Therapeutic Goods Administration (TGA), before they can be lawfully imported, supplied or exported as medicines. Pemvidutide is not listed on the ARTG and is not TGA-approved.

As an unapproved investigational compound, pemvidutide is not available as an approved medicine in Australia. It is supplied by NovaPeptides for laboratory research use only. This is distinct from an approved medicine: an approved medicine has been assessed by a regulator and entered on the ARTG, whereas a research compound has not and is intended for use in a controlled research setting, not for human treatment.

Pemvidutide and other metabolic compounds

Pemvidutide can be placed in context against other molecules in the metabolic research field, purely at the level of drug class and mechanism. These are structural and pharmacological distinctions, not statements that one compound is better or more suitable than another for any purpose.

Mechanistic class, in brief

• Single GLP-1 receptor agonists act at one receptor, the GLP-1 receptor, only.
• Pemvidutide is described as a GLP-1 and glucagon (GCGR) dual receptor agonist, activating two receptors.
• Survodutide (code name BI 456906, developed by Boehringer Ingelheim) is another investigational GLP-1 and glucagon dual agonist, so it shares the same receptor-pairing class as pemvidutide.
• Some other dual agonists pair the GLP-1 receptor with a different second receptor, which is a mechanistically distinct combination from the GLP-1 and glucagon pairing.

The point of this comparison is only to show where pemvidutide sits among research-stage molecules by mechanism. It is not a recommendation and makes no claim about effects in any person.

Research use only: what it means

Research use only means a compound is intended solely for laboratory and scientific research conducted by appropriately qualified researchers in a controlled setting. It is not intended for human or veterinary use, not for diagnostic use, and not for any form of self-administration.

Because pemvidutide is an unapproved investigational compound, NovaPeptides supplies it on a research-use-only basis. We do not provide dosing information, administration instructions, protocols or any human-use guidance, and nothing on this page should be read as such. Anyone handling research compounds is responsible for complying with all applicable laws and institutional requirements.

How NovaPeptides supplies pemvidutide

NovaPeptides lists pemvidutide as a research compound for laboratory research use only. Where available, products are accompanied by a Novagen certificate of analysis (COA) so that researchers can review documented identity and purity information for the item they receive.

What to expect

• Research-use-only supply, not for human use.
• Novagen COA documentation where available.
• Australian-based dispatch and shipping.
• No dosing, protocol or administration guidance of any kind.

If you need documentation for a research compound, the COA is the appropriate reference. For anything concerning health, medicines or your individual circumstances, speak with a qualified healthcare professional. This page remains general information only and is not legal or medical advice.

Frequently asked questions